Total Payments
$2.9M
2024 Payments
$642,055
Companies
13
Transactions
3,439
Payment Breakdown by Category
Other$2.2M (77.1%)
Travel$353,926 (12.2%)
Consulting$256,786 (8.9%)
Food & Beverage$47,544 (1.6%)
Education$4,195 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.2M | 740 | 75.0% |
| Travel and Lodging | $353,926 | 1,727 | 12.2% |
| Consulting Fee | $256,786 | 82 | 8.9% |
| Honoraria | $61,522 | 78 | 2.1% |
| Food and Beverage | $47,544 | 803 | 1.6% |
| Education | $4,195 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $562,072 | 539 | $0 (2024) |
| Allergan, Inc. | $526,509 | 641 | $0 (2021) |
| Alkermes, Inc. | $368,234 | 374 | $0 (2023) |
| Axsome Therapeutics, Inc. | $336,903 | 432 | $0 (2024) |
| ITI, Inc. | $301,369 | 304 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $237,208 | 284 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $212,734 | 381 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $165,150 | 262 | $0 (2019) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $102,877 | 102 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $45,809 | 60 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $642,055 | 714 | Vanda Pharmaceuticals Inc. ($225,570) |
| 2023 | $392,709 | 432 | ABBVIE INC. ($146,774) |
| 2022 | $331,996 | 366 | ABBVIE INC. ($146,005) |
| 2021 | $193,530 | 184 | AbbVie Inc. ($128,809) |
| 2020 | $188,991 | 197 | Allergan, Inc. ($116,023) |
| 2019 | $336,341 | 417 | Allergan Inc. ($160,994) |
| 2018 | $494,376 | 703 | Allergan Inc. ($141,807) |
| 2017 | $311,223 | 426 | Allergan Inc. ($102,060) |
All Payment Transactions
3,439 individual payment records from CMS Open Payments — Page 1 of 138
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,215.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,215.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/26/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,538.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,215.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,215.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $110.04 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $33.84 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $27.39 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $13.89 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,215.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $518.17 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $386.21 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $121.85 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $33.97 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $33.84 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $456.94 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $274.50 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $140.77 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $116.55 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $62.80 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $1,525.12 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $191.87 | General |
| Category: Psychiatry/Psychology | ||||||
About Dr. Richard Petty, M.D
Dr. Richard Petty, M.D is a Psychiatry healthcare provider based in Loganville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1730334079.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Petty, M.D has received a total of $2.9M in payments from pharmaceutical and medical device companies, with $642,055 received in 2024. These payments were reported across 3,439 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.2M).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Acupuncturist
- Location Loganville, GA
- Active Since 12/01/2008
- Last Updated 12/01/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1730334079
Products in Payments
- VRAYLAR (Drug) $1.1M
- CAPLYTA (Drug) $404,246
- Auvelity (Drug) $336,903
- FANAPT (Drug) $237,208
- LATUDA (Drug) $212,734
- Trintellix (Drug) $201,587
- Aristada 441 mg (Drug) $190,259
- ARISTADA (Drug) $177,975
- COBENFY (Drug) $28,308
- SPRAVATO (Drug) $3,007
- Entyvio (Biological) $196.20
- TRINTELLIX (Drug) $174.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.